Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

PBE vs. BIB: which is better?

Bottom line

PBE vs BIB: the short answer

PBE (Invesco Biotechnology & Genome ETF) and BIB (ProShares Ultra Nasdaq Biotechnology) are quite different portfolios: only about 31% of their top holdings (by weight) are shared.

But BIB is far broader, holding 267 positions to 33 for PBE, so beyond the top names it adds exposure PBE doesn't have.

PBE is cheaper at 0.59% vs 0.95% — a difference of $36 a year per $10,000 invested.

Over five years, PBE returned +3.4% a year vs −1.0% for BIB.

Updated Nov 19, 2026

PBE vs BIB side by side

PBEBIB
TypeETFETF
Fund familyInvescoProShares
CategoryTechnology SectorTechnology Sector
Expense ratio0.59%0.95%
Annual cost per $10k$59$95
10-yr cost on $10k (prospectus)$738$1,401
Max front loadNoneNone
12b-1 fee——
1-yr return+24.7%+59.3%
5-yr return (annualized)+3.4%−1.0%
10-yr return (annualized)+5.2%+1.4%
Best quarter+25.3%+56.2%
Worst quarter−24.3%−42.7%
Net assets (fund)$281.9M$73.7M
Number of holdings33267
Portfolio turnover103%29%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearPBEBIBDifference
2025+24.7%+59.3%−34.6%
2024+1.1%−10.0%+11.1%
2023+3.7%−1.3%+5.0%
2022−10.8%−28.6%+17.9%
2021+1.6%−5.9%+7.5%
2020+25.5%+39.7%−14.2%
2019+18.3%+45.5%−27.3%
2018+0.2%−24.4%+24.6%
2017+22.4%+40.8%−18.3%
2016−23.0%−44.2%+21.2%

Source: Fund prospectus bar charts

Holdings overlap

9 of PBE's top 25 holdings also appear in BIB's top 25.

Shared top holdings
HoldingPBEBIB
Regeneron Pharmaceuticals, Inc.5.47%3.21%
Amgen Inc.5.22%4.48%
Vertex Pharmaceuticals Inc.4.99%4.65%
Biogen Inc.4.79%1.44%
Gilead Sciences, Inc.4.43%4.66%
United Therapeutics Corp.4.08%1.22%
Illumina, Inc.3.51%1.25%
Alnylam Pharmaceuticals, Inc.3.17%2.01%
Incyte Corp.3.06%0.97%

Source: SEC Form N-PORT

PBE top 10

  1. Invesco Private Prime Fund — 12.89%
  2. Regeneron Pharmaceuticals, Inc. — 5.47%
  3. Amgen Inc. — 5.22%
  4. CareDx, Inc. — 5.04%
  5. Vertex Pharmaceuticals Inc. — 4.99%
  6. Invesco Private Government Fund — 4.97%
  7. Royalty Pharma PLC — 4.94%
  8. Biogen Inc. — 4.79%
  9. Gilead Sciences, Inc. — 4.43%
  10. United Therapeutics Corp. — 4.08%

BIB top 10

  1. N/a — 7.35%
  2. ProShares GENIUS Money Market ETF — 6.80%
  3. Gilead Sciences, Inc. — 4.66%
  4. Vertex Pharmaceuticals, Inc. — 4.65%
  5. Amgen, Inc. — 4.48%
  6. N/a — 3.94%
  7. N/a — 3.26%
  8. Regeneron Pharmaceuticals, Inc. — 3.21%
  9. N/a — 2.62%
  10. Alnylam Pharmaceuticals, Inc. — 2.01%

FAQ

What is the difference between PBE and BIB?
PBE (Invesco Biotechnology & Genome ETF) and BIB (ProShares Ultra Nasdaq Biotechnology) are quite different portfolios: only about 31% of their top holdings (by weight) are shared. But BIB is far broader, holding 267 positions to 33 for PBE, so beyond the top names it adds exposure PBE doesn't have.
Which is cheaper, PBE or BIB?
PBE has the lower expense ratio (0.59%).
Should I own both PBE and BIB?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.